NaturalAntibody collaborates with Boehringer Ingelheim in the Computational Discovery of Therapeutic Antibodies

4 April 2023 – NaturalAntibody S.A. announces a strategic collaboration with Boehringer Ingelheim to develop and apply digital methods for the development of therapeutic monoclonal antibodies (mAbs) with the aim of accelerating the discovery of new biotherapeutics in areas of high unmet patient need.
Therapeutic mAbs have become the predominant treatment modality in many disease areas, especially in cancer, autoimmune, and infectious diseases. But despite major technological advances the discovery and development of mAbs has remained a complex and time-consuming process, and many disease-relevant targets cannot be addressed because they are challenging to make.

NaturalAntibody has developed an artificial intelligence-reinforced platform that could transform this process, accelerating the development of mAbs and opening a discovery route for mAbs against difficult to make targets. The new collaboration combines NaturalAntibody’s cutting-edge digital solutions with Boehringer Ingelheim’s experience in data generation and laboratory validation to develop and benchmark novel methods for computational antibody discovery, characterization, and development, potentially benefitting Boehringer Ingelheim’s therapeutic antibody development.
Founder and Chief Executive Officer at NaturalAntibody Konrad Krawczyk said:

“We are looking forward to the strategic collaboration with Boehringer Ingelheim. NaturalAntibody’s data and machine learning expertise is a powerful match with Boehringer Ingelheim’s leading expertise in the development of therapeutic mAbs and could help bringing new breakthrough therapies to patients faster”